Moderate Evidence Points To Safety And Quality-Of-Life Gains In Hard-To-Treat Patients
We’re pulling this article from our vault because it’s one of our most popular reads, and with good reason. Hidradenitis suppurativa (HS) disproportionately impacts women, minorities, and those with darker skin tones, yet many patients fail to find lasting relief. A focused review of seven studies now reveals that botulinum toxin injections led to clinical improvement or enhanced quality of life in 96.8 percent of cases, without serious adverse events.
Although the evidence level remains moderate and patient numbers are small, the consistent positive outcomes align with botulinum toxin’s known ability to modulate local inflammation and sweat gland activity. For dermatologists facing refractory HS, this vault favorite offers a compelling rationale to consider botulinum toxin as an adjunctive therapy.
As we continue to confront disparities in HS care, let’s harness the momentum of this popular study: integrate botulinum toxin into select treatment plans, rigorously track patient responses, and champion larger, high-quality trials. By doing so, we can turn this promising insight into a standard of care for those who need it most.
J Drugs Dermatol. 2022;21(04): doi:10.36849/JDD.5747
Blog write-up assisted by AI
